Vivani Medical And Okava Expand Collaboration To Develop Okv-119 For Dogs, Targeting Metabolic Health And Longevity

Vivani Medical, Okava Expand Weight-Loss Drug Collaboration to Include Dogs

Vivani Medical And Okava Expand Collaboration To Develop Okv-119 For Dogs, Targeting Metabolic Health And Longevity

Vivani Medical, Inc. and Okava Pharmaceuticals, Inc. Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Vivani Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024

Vivani Medical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024

Vivani Medical Announces $8.25M Private Placement Equity Financing

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

Vivani Medical, Inc. Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Y Early Dosing

Vivani Medical, Inc. announced that it expects to receive $8.25 million in funding

Vivani Medical Completes Enrollment, Begins Dosing in Diabetes Implant Trial

Vivani Medical Achieves First Implant And Full Enrollment In The First-In-Human Clinical Trial Of GLP-1 Implant NPM-115 In Obese Or Overweight Adults

Vivani Medical, Inc. Achieves First Implant and Full Enrollment in the First-In-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

Vivani Medical intends to spin off brain implants division

Vivani Medical Plans to Spin Off Cortigent Neurostimulation Business

Vivani Medical, Inc. agreed to Spin-Off Cortigent, Inc.

Vivani Medical, Inc. Announces First-In-Human Clinical Trial, Known as LIBERATE-1?

Vivani Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024

Earnings Flash (VANI) VIVANI MEDICAL Posts Q3 Loss $-0.11 Per Share

Vivani Medical, Inc. announced that it expects to receive $4.999999 million in funding

HC Wainwright Starts Vivani Medical With Buy Rating, $3 Price Target

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical, Inc. Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024

Earnings Flash (VANI) VIVANI MEDICAL Posts Q2 Loss $-0.10

Vivani Medical, Inc. Provides Update on Clinical Development Plans for Miniature, Long-Term, GLP-1 Obesity Implant Program, NPM-115